Successful utilization of nirmatrelvir/ritonavir and dexamethasone in a patient with total artificial heart and COVID-19: A case report

Author:

Alowais Shuroug A.123,Bosaeed Mohammed245,Saleh Khalid Bin123,AlQahtani Hajar123,Selimovic Nedim24,Ahmed Husnat24,Alghamdi Abdullah A.245,Hussain Arif24,Badreldin Hisham A.123ORCID

Affiliation:

1. College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, City, Saudi Arabia

2. King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

3. Pharmaceutical Care Department, National Guard Health Affairs, Riyadh, Saudi Arabia

4. King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia

5. College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

Abstract

Rationale: Management of coronavirus disease 2019 (COVID-19) has been the subject of extensive research and study, leading to the development of strategies and treatments. Nonetheless, there remains a dearth of information concerning patients who require mechanical circulatory system support. This case report presents one of the first documented cases of successful utilization of nirmatrelvir/ritonavir (Paxlovid) and dexamethasone in the treatment of a patient with a total artificial heart. Patient concerns: The patient in this case study was a 28-year-old male who had been experiencing severe heart failure. In need of a heart transplant, he underwent a procedure for implantation of a total artificial heart as a bridge to transplantation. Diagnoses: Unfortunately, after the surgical intervention, the patient contracted COVID-19, as confirmed by polymerase chain reaction. Interventions: The therapeutic approach involved a 5-day regimen of nirmatrelvir/ritonavir at a dosage of 300/100 mg administered twice daily, along with a daily dosage of 6 mg of dexamethasone. Outcomes: Remarkably, the patient oxygenation level improved on the second day of therapy. Consequently, he was transferred from the intensive care unit to the general floor. After 71 days with the total artificial heart, the patient successfully underwent heart transplantation. Lessons: This case report provides a compelling example of the successful application of nirmatrelvir/ritonavir and dexamethasone in the treatment of a COVID-19 patient with a total artificial heart. The positive outcome observed in this case underscores the potential use of these therapeutic agents in this specific patient population. However, it is imperative to conduct further research to corroborate and validate these initial findings. This study lays the foundation for further exploration of the efficacy of these drugs in patients with mechanical circulatory support systems.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference10 articles.

1. A new coronavirus associated with human respiratory disease in China.;Wu;Nature,2020

2. Comorbidities and mortality in COVID-19 patients.;Djaharuddin;Gac Sanit,2021

3. Clinical characteristics and outcomes of patients with heart failure admitted to the intensive care unit with coronavirus disease 2019 (COVID-19): a multicenter cohort study.;Saleh;Am Heart J Plus,2021

4. Prognostic impact of prior heart failure in patients hospitalized with COVID-19.;Alvarez-Garcia;J Am Coll Cardiol,2020

5. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.;Heidenreich;Circulation,2022

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3